UCSF studies illuminate possible new landscape for targeting cancer

Dual UCSF findings dramatize what scientists have just begun to recognize: While so-called oncogenic cells drive the development of cancerous tumors, other, seemingly innocent cells -- inflammatory cells - within emerging tumors can influence the fate of tumors, their aggression and their response to therapy.

The findings, both reported in recent publications, suggest that blocking the action of these 'innocent' cells - or the factors they release - may interrupt the progression of cancerous tumors at early stages of development, the researchers say.

"Tumor biology has historically focused on the cells that contain oncogenic or tumor-suppressor gene mutations. But the combined implication of our two studies suggests that we need to look beyond the mutated tumor cells and into their micro-environment, to take into account the regulation of inflammatory cells," says the lead author of one study, published in Cell, Lisa Coussens, PhD, assistant professor of pathology and a member of the UCSF Comprehensive Cancer Center.

In the Cell study, the researchers report that an enzyme known as matrix metalloproteinase-9 (MMP-9) significantly influences the progression of cancer development in mice engineered to express oncogenes, or tumor-causing genes, that predispose animals to develop squamous cell carcinomas, a common skin cancer in humans. Moreover, the researchers demonstrate that the primary source of the enzyme is not the oncogenic epithelial cells that drive the cancer, but immune inflammatory cells within the tumor's developing mass.

In the other study, published in Nature Cell Biology, the researchers demonstrate that the same enzyme is a key component of the "switch" that initiates angiogenesis, the growth of blood vessels, in mice genetically engineered to develop carcinomas of the pancreatic islets. Angiogenesis supplies emerging tumors with the nutrients and oxygen that are essential for fueling their progressi

Contact: Jennifer O'Brien
University of California - San Francisco

Page: 1 2 3 4 5

Related biology news :

1. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
2. UCSD undergraduates participate in collaborative studies abroad on cyberinfrastructure
3. Scientist honored for studies of genetic influence on chemotherapy, tumor development
4. $5 million grant funds partnership, studies of minority-based issues in reproductive health
5. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
6. $5.5 million awarded to tree-ring research and climate studies
7. Pancreatic cancer blood test & gene studies show promise
8. Two studies weigh in on low-carb diets
9. Animal studies show promise treating severe chronic pain
10. New studies show Curves Program raises metabolic rate in overweight and sedentary women
11. Florida Tech researchers win $912,700 grant for cell studies

Post Your Comments:

(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
Cached News: